Amgen Inc. (AMGN) Stock Analysis
Is AMGN a good investment?
Amgen Inc. (AMGN) has a Plutrex AI rating of 34.0/100 as of August 20, 2026, indicating a Sell consensus. The stock is not classified as halal-compliant. Key strength: Exceptional profitability moat: gross margin 72.71% (+5.5% vs. industry 68.94%), operating margin 35.55% (+18.6% vs. industry 29.98%), net margin 22.89% (+54.3% vs. industry 14.83%), and FCF $8.65B annually — the cash engine that services $27.8B Horizon debt and sustains the $9.00+ annual dividend with room to spare. Main concern: Catastrophic valuation mismatch WORSENED: PEG 3.27x vs. industry 1.79x (82.5% premium to peers) for only 5.55% 5-year EPS growth; analyst consensus target $390.15 is now 11.8% BELOW current price $442.36 (vs. 7.7% below at prior report); stock has risen 6.3% since prior Sell rating while analyst target rose only 1.6% ($383.85 → $390.15), meaning the overvaluation gap has WIDENED by ~4.7 percentage points; applying fair multiples (15-18x earnings on ~$16.10 EPS) yields intrinsic value $242-$290, implying 34-45% downside from current levels.
Investment Summary
Amgen (AMGN) at $442.36 is a world-class biologic manufacturer trading at a severe valuation premium that fundamentals cannot justify. The stock has risen 6.3% since our prior Sell rating ($416.18 → $442.36), widening the overvaluation gap further. The analyst consensus target of $390.15 implies -11.8% downside from current levels — meaning even optimistic sell-side analysts believe the stock is worth less than it trades today. The PEG ratio of 3.27x (vs. industry average 1.79x, an 82.5% premium) is the defining metric: investors are paying 3.27 times the expected growth rate for a company projected to grow EPS at only 5.5% annually over 5 years. The P/E of 27.48x on 5.5% forward EPS growth is deeply inconsistent — a fair P/E for this growth profile is 15-18x, implying intrinsic value of $242-$290. The D/E ratio of 4.44x (vs. industry 1.78x, 149.7% above peers) from the $27.8B Horizon acquisition adds a structural risk discount. Positive news — Q2 revenue beat, $1B guidance raise, broad portfolio strength — is genuine but already priced into the stock's 6.3% post-earnings surge. BlackRock's 9.15% stake provides governance stability but not valuation support. The data breach disclosure is a minor negative. At $442.36, the risk/reward is deeply unfavorable: upside to analyst consensus is -$52.21 (-11.8%), while downside to fair value is -$150 to -$200 (-34% to -45%).
Key Strengths
- Exceptional profitability moat: gross margin 72.71% (+5.5% vs. industry 68.94%), operating margin 35.55% (+18.6% vs. industry 29.98%), net margin 22.89% (+54.3% vs. industry 14.83%), and FCF $8.65B annually — the cash engine that services $27.8B Horizon debt and sustains the $9.00+ annual dividend with room to spare
- Q2 2026 operational momentum confirmed: revenue exceeded $10B (+9.5% YoY), raised full-year 2026 financial outlook by ~$1B, broad portfolio growth across multiple medicines demonstrating commercial execution and product diversification — headline 'Amgen Hikes Sales Outlook By $1 Billion After Second-Quarter Smash' confirms genuine business strength
- MariTide obesity pipeline optionality: monthly dosing differentiation vs. weekly injectables (Lilly/Novo) in a $100B+ addressable market, plus GLP-1 adjacent positioning (headline: 'GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit') represents significant unpriced upside if Phase 3 data supports the profile — the one catalyst that could materially re-rate the stock above analyst consensus
Key Concerns
- Catastrophic valuation mismatch WORSENED: PEG 3.27x vs. industry 1.79x (82.5% premium to peers) for only 5.55% 5-year EPS growth; analyst consensus target $390.15 is now 11.8% BELOW current price $442.36 (vs. 7.7% below at prior report); stock has risen 6.3% since prior Sell rating while analyst target rose only 1.6% ($383.85 → $390.15), meaning the overvaluation gap has WIDENED by ~4.7 percentage points; applying fair multiples (15-18x earnings on ~$16.10 EPS) yields intrinsic value $242-$290, implying 34-45% downside from current levels
- Extreme leverage + structural growth deficit UNCHANGED: D/E 4.44x vs. industry 1.78x (149.7% above peers) from Horizon acquisition unchanged; 5-year EPS CAGR 5.55% vs. industry 8.17% (32.1% below peers); forward next-year EPS growth 5.84% vs. industry 154.42% (96.2% below peers) — Amgen remains the slowest-growing major pharma in its peer group while carrying the most leverage; data breach disclosure ('Amgen discloses data breach, says patient information was stolen') adds minor reputational/regulatory risk on top of existing structural concerns
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
Amgen's fundamentals present a tale of two cities. PROFITABILITY EXCELLENCE: Gross margin 72.71% (vs. industry 68.94%, +5.5% premium), operating margin 35.55% (vs. industry 29.98%, +18.6% premium), net margin 22.89% (vs. industry 14.83%, +54.3% premium), FCF $8.65B annually, cash $13.99B. ROE of 91.5% is leverage-amplified (D/E 4.44x) but reflects genuine operational excellence. GROWTH DEFICIT: Forward next-year EPS growth 5.84% (vs. industry 154.42%, a 96.2% discount to peers — Amgen is the slowest-growing major pharma in its peer group). 5-year EPS CAGR 5.55% (vs. industry 8.17%, 32.1% below peers). Revenue growth 9.5% is respectable but trailing EPS growth of only 2.6% YoY shows revenue is not converting to per-share value. VALUATION CRISIS: P/E 27.48x on 5.5% growth yields PEG 3.27x (vs. industry 1.79x). Applying fair-value PEG of 1.5x to 5.5% growth implies fair P/E ~8.25x; even at a generous quality premium of 18x P/E, intrinsic value is ~$290. Analyst consensus $390.15 implies -11.8% downside. BALANCE SHEET RISK: D/E 4.44x vs. industry 1.78x — Amgen carries 2.5x more leverage than the average peer. The 12.6pp gap between operating margin (35.55%) and net margin (22.89%) is almost entirely interest expense from Horizon debt. FCF of $8.65B provides debt service capacity but constrains financial flexibility.
News Sentiment
Amgen is riding a wave of genuine business momentum — but Wall Street's enthusiasm may be getting ahead of itself. The biotech giant recently delivered a blockbuster second quarter, with sales rising 9% and profits topping Street expectations, prompting management to hike its full-year sales outlook by a stunning $1 billion. The headline 'Amgen Hikes Sales Outlook By $1 Billion After Second-Quarter Smash' tells the story of a company firing on all cylinders, with growth across key medicines offsetting competitive pressure on its bone-health franchise. Adding to the excitement, Amgen is positioning itself as a potential winner in the red-hot GLP-1 weight-loss drug market — a sector that's 'soaring' according to analysts — through its experimental MariTide drug, which offers a monthly dosing advantage over weekly shots from Eli Lilly and Novo Nordisk. One analyst even argues 'The Market Is Underestimating Its Next Growth Phase.' But not everything is rosy. The company disclosed a data breach in which patient information was stolen — a serious privacy incident that could invite regulatory scrutiny and legal costs. And despite the operational wins, at least one independent analysis suggests the stock may be overvalued by approximately 40% based on discounted cash flow models. With investment giant BlackRock holding a 9.15% stake, Amgen has powerful institutional backing — but powerful shareholders don't automatically make an expensive stock cheap.
Risk Assessment
PRIMARY RISK — VALUATION COMPRESSION: At P/E 27.48x on 5.5% EPS growth (PEG 3.27x), any multiple compression toward fair value (15-18x) implies 34-45% downside to $242-$290. The analyst consensus of $390.15 itself implies -11.8% from current price. SECONDARY RISK — LEVERAGE STRESS: D/E 4.44x means rising interest rates or revenue disruption could rapidly impair FCF available for debt service and dividends. The 12.6pp operating-to-net margin gap is almost entirely interest expense — any revenue miss amplifies this. TERTIARY RISK — PIPELINE FAILURE: MariTide Phase 3 failure would remove the primary re-rating catalyst and likely accelerate multiple compression. MINOR RISK — DATA BREACH: 'Amgen discloses data breach, says patient information was stolen' — potential regulatory fines (HIPAA), reputational damage, and litigation costs; manageable given FCF but adds uncertainty. MITIGATION: The $8.65B FCF and $13.99B cash provide a meaningful buffer against near-term distress. The dividend ($9.00+/year) is well-covered by FCF. BlackRock's 9.15% stake provides governance stability. The business will not collapse — but the stock price can compress significantly without any operational deterioration simply through multiple normalization.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is AMGN a halal stock?
No, Amgen Inc. (AMGN) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for AMGN?
Amgen Inc. (AMGN) has a Plutrex AI rating of 34.0/100 with a Sell consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is AMGN a good investment?
According to Plutrex AI, AMGN has a Sell rating (34.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in AMGN?
US stocks like AMGN can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in AMGN?
Plutrex AI identifies the main risks for AMGN by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.